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OBJECTIVES: To summarize published data on the burden of
GAD to assist decision makers in the UK. METHODS: A
review of published studies on the human, health care and eco-
nomic burden of GAD in the UK. Studies were identiﬁed
through searches in electronic databases (MEDLINE/EMBASE)
and reference lists of published articles. RESULTS: GAD was
identiﬁed as the most prevalent speciﬁc neurotic disorder among
adults in the general population of the UK (44 adults per
1,000). GAD respondents reported signiﬁcant impairments in
mental and physical health status. GAD was associated with a
signiﬁcant increase in odds of not working (compared to
working) that was nearly twice that of the rest of the sample,
after adjusting for physical health and sociodemographic char-
acteristics (adjusted OR = 1.79). GAD also showed signiﬁcant
increases in odds associated with difﬁculties performing seven
activities of daily living; a similar pattern of ﬁndings was
observed for depressive episode, but not for the other speciﬁc
neurotic disorders (phobias, obsessive-compulsive disorder, and
panic disorder). Despite the high prevalence of GAD and its
association with impairment, 67% people with GAD in the
community were not receiving treatment for a mental/emotional
problem; this proportion was higher than that reported by the
other speciﬁc neurotic disorder groups. In contrast, GAD was
the most common anxiety disorder in primary care in general
(7%) and in a subgroup of somatizing patients in particular.
Findings suggest that GAD patients may be more likely to seek
help for a medical problem than for a mental/emotional
problem. The per-patient cost of GAD in the UK (€2184 in
2004) was higher than that of any other anxiety disorder con-
sidered, owing to lost work productivity and high health care
utilization. CONCLUSION: GAD is a prevalent and burden-
some disorder in the UK. Improved recognition and treatment
of GAD should be an important public health priority.
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HEALTH RESOURCES CONSUMPTION AND COST OF MANIC
EPISODE IN SPAIN
Tafalla M, Cordero L, Diez T, Hernandez R
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OBJECTIVES: Bipolar Disorder (BD) is a chronic affective
disorder characterized by recurrent manic, hypomanic and
depressive episodes. The objective of the present study was
to estimate the health resource use of a large sample of bipo-
lar patients during a manic episode (DSM IV criteria).
METHODS: Cross-sectional study conducted in 181 psychiat-
ric outpatient ofﬁces in Spain using medical charts and patient
reports. Observation period included the index manic episode
up to a maximum of 4 months. Health resources utilization
during the period, including hospitalisation days, outpatient
resources and drug consumption were collected. All the costs
were expressed as 2007 €. RESULTS: A total of 794 patients
were evaluable (54.8% women; mean age: 43.5  12.1 years),
with manic episode mean duration of 76.4  43 days. Fifty
percent of the patients were hospitalised for a mean hospital
stay of 22.9  15.5 days. Factors related to hospitalisation
were marital status (married patients less likely and place of
residence (rural area patients more than urban ones ). Regard-
ing outpatient resource use, mean number of visits to
attending psychiatrist was 5.7  10.3 times; psychologist
0.8  2.4, psychiatric nurse 1.6  4.3, primary care physician
1.9  6.0, other specialists 0.3  1.4, lithium lab 1.3  3.1,
psychotherapy 0.6  10.8. Emergency room mean visits during
the index episode was 1.0  2.8 and 0.6  1.8 to hospital and
outpatient emergency facilities. No differences were found in
outpatient resources utilization regarding demographic vari-
ables or disease course. Regarding drug use, 87.8% of patients
were given atypical antipsychotics, 81.1% mood stabilizers and
53.5% hypnotics/anxiolytic during the observation period.
Mean total cost of management of a manic episode was
4345  4019.4 euros, of which 56.7% were hospitalization
costs, 29.5% were drug costs and 13.9% were outpatient treat-
metn costs. CONCLUSION: Hospitalization costs are the main
cost driver in the management of a manic episode in Spain.
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PROPENSITY SCORE MATCHING
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OBJECTIVES: The overall purpose of this research endeavor
was to evaluate changes in health care costs associated with a
comprehensive disease management program for Medicaid
clients with schizophrenia plus other medical comorbidities
within the State of Colorado, United States. METHODS: This
retrospective database analysis employed a pre-post analysis
for disease management clients relative to a propensity-score
matched comparator group. Direct costs based upon compre-
hensive medical and pharmacy claims were assessed from the
perspective of a public payer. Data analyzed included patient
demographics, medical and pharmacy administrative resource
utilization claims and costs, diagnostic information, eligibility
and enrollment information, and program-related information
from an independent, private, external disease management
vendor. Multivariate regression techniques were utilized to
ascertain differences between the disease management and
propensity-score matched comparator groups. RESULTS: Of
the 350 clients contacted for eligibility, 73 (21%) remained
enrolled continuously for six to 12 months. Provision of the
disease management program through the external vendor cost
$31,250 per month regardless of the number enrolled. Not
including costs these program costs, the disease management
program was associated with 30 percent lower overall
per member per month (PMPM) medical costs (p < 0.001),
although no differences were noted for other cost categories.
CONCLUSION: Care for Medicaid clients with schizophrenia
involves several unique and important issues that must be con-
sidered in both the development and delivery of an effective
disease management program. This investigation found signiﬁ-
cant reductions in total medical costs following the implemen-
tation of a disease management program, although costs to
deliver the interventions exceeded any resultant cost savings.
Furthermore, a relatively small percentage of those eligible for
participation ultimately completed six months or more of the
program. Future research should seek to assess long-term clini-
cal, humanistic, and economic outcomes in this population and
in developing methods that increase program participation.
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